Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer

European Urology, 04/23/2012

The approval of agents for advanced prostate cancer underscores the importance of androgen pathway inhibition, immunotherapy, tubulin antagonists, and pathophysiology of bone metastasis. Trials are also targeting pathways that modulate invasion, and angiogenesis.

Print Article Summary Cat 2 CME Report